-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai, September 27, 2021/PRNewswire/ - WuXi Giant Nuo (HKEx code: 2126), an innovative biotechnology company focused on the development, production and commercialization of cellular immunotherapy products, today announced its The application for a clinical trial targeting BCMA chimeric antigen receptor (CAR) T cell JWCAR129 for the treatment of relapsed/refractory multiple myeloma has been approved by the National Medical Products Administration (NMPA) of China
Multiple myeloma (MM) is an incurable hematological tumor that starts in the bone marrow and is characterized by excessive proliferation of plasma cells
references:
1.
2.
3.
4.
About WuXi Giant Nuo
WuXi Giant Nuo (HKEx code: 2126) is an innovative biotechnology company focusing on the development, production and commercialization of cellular immunotherapy products
Forward-looking statement
The forward-looking statements contained in this release are based on management’s current expectations and confidence, and there are certain uncertainties or risks that may cause actual results to be substantially different from those described
Source: WuXi Juno